Identifying the Risks of Unproven Regenerative Medicine Therapies
A new paper published on JAMA by Peter W. Marks and Stephen Hahn of FDA The products administered by clinics under the broad rubric of regenerative medicine include those derived from individuals’ own bone marrow or fat, those derived from birthing tissues such as placenta or cord blood obtained from a donor unrelated to the